E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder (MDD) |
|
E.1.1.1 | Medical condition in easily understood language |
Major Depressive Disorder |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012378 |
E.1.2 | Term | Depression |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of lurasidone (20, 40, and 60 mg/day, flexibly dosed) compared to placebo for the treatment of subjects with major depressive disorder (MDD) currently experiencing a major depressive episode (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR]) with mixed features as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. |
|
E.2.2 | Secondary objectives of the trial |
Mean change from baseline to endpoint in the Young Mania Rating Scale (YMRS) total score
Mean change from baseline to endpoint in the Sheehan Disability Scale (SDS) total score and SDS subscale scores
Mean change from baseline to endpoint in the Hamilton Rating Scale for Anxiety (HAM-A) total score
Safety end tolerability |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
Subject is 18 to 75 years of age, inclusive.
Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured Clinical Interview for DSM-IV Disorders – Clinical Trial version [SCID-CT]).
Subject is currently experiencing a major depressive episode (diagnosed by DSM-IV-TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Lurasidone Protocol D1050304):
o Elevated, expansive mood
o Inflated self-esteem or grandiosity
o More talkative than usual or pressure to keep talking
o Flight of ideas or subjective experience that thoughts are racing
o Increase in energy or goal-directed activity (either socially, at work or school, or sexually)
o Increased or excessive involvement in activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
o Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia)
Subject has a rater-administered Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥ 26 at screening and both a rater-administered and self-rated (administered by computer) MADRS total score ≥ 26 at baseline. |
|
E.4 | Principal exclusion criteria |
Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening.
Subject answers “yes” to “Suicidal Ideation” Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.
Subject has attempted suicide within the past 3 months.
Subject has a lifetime history of any bipolar I manic or mixed manic episode.
Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the mean change from baseline to the 6-week study endpoint in MADRS total score. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The key secondary endpoint is the mean change from baseline to
the 6-week study endpoint in CGI-S score
Other secondary endpoints include the following:
Mean change from baseline to endpoint in the YMRS total score
Mean change from baseline to endpoint in the SDS total score and SDS subscale scores
Mean change from baseline to endpoint in the HAM-A total score
Proportion of subjects who achieve a response, defined as ≥ 50% reduction from baseline on the MADRS total score at endpoint
Proportion of subjects who achieve a remission, defined as a MADRS total score of ≤ 12 at endpoint
Proportion of subjects with treatment-emergent mania, assessed by a YMRS total score of ≥ 16 on any two consecutive visits or at the final assessment, or an AE of mania or
hypomania
The safety objectives of this study include evaluation of the following:
Proportion of subjects with AEs and SAEs, and discontinuations due to AEs and SAEs
Vital signs and ECG measurements
Movement disorders assessed by the AIMS, BARS, and SARS
Weight and laboratory measures
Mean change from baseline to endpoint in sexual functioning based on CSFQ total score and CSFQ subscale scores
Frequency and severity of suicidality using C-SSRS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Russian Federation |
Serbia |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |